4-hydroxyphenylacetic acid

CAS No. 156-38-7

4-hydroxyphenylacetic acid( —— )

Catalog No. M18084 CAS No. 156-38-7

4-Hydroxybenzeneacetate acid is considered to be slightly soluble (in water) and acidic. 4-Hydroxybenzeneacetate acid can be synthesized from acetic acid.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 37 In Stock
200MG 52 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    4-hydroxyphenylacetic acid
  • Note
    Research use only, not for human use.
  • Brief Description
    4-Hydroxybenzeneacetate acid is considered to be slightly soluble (in water) and acidic. 4-Hydroxybenzeneacetate acid can be synthesized from acetic acid.
  • Description
    4-Hydroxybenzeneacetate acid is considered to be slightly soluble (in water) and acidic. 4-Hydroxybenzeneacetate acid can be synthesized from acetic acid. It can be found throughout numerous foods such as Olives, Cocoa beans, Oats, and Mushrooms. 4-Hydroxybenzeneacetate acid can be found throughout all human tissues and in all biofluids. Within a cell, 4-Hydroxybenzeneacetate acid is primarily located in the cytoplasm and in the extracellular space.(In Vivo):4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1.
  • In Vitro
    ——
  • In Vivo
    4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    156-38-7
  • Formula Weight
    152.15
  • Molecular Formula
    C8H8O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL; 657.25 mM
  • SMILES
    OC(=O)Cc1ccc(cc1)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Egg Laying Hormone, ...

    Egg-laying hormone (ELH) is a neuropeptide synthesized by the bag cell neurons, Egg-laying hormone (ELH) induces egg laying and its correlated behavior in Aplysia californica. Egg-laying hormone (ELH) has been purified to homogeneity and Egg-laying hormone (ELH)'s primary structure has been determined. Egg-laying hormone (ELH) have 36 amino acid residues with a Mr of 4385 and a calculated isoelectric point of 9.7. Egg Laying Hormone of Aplysia induces a voltage-dependent slow inward current carried by Na+ in an identified motoneuron.

  • Tocofersolan

    Tocofersolan is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of Tocopherol. Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis.

  • ProTx III

    Potent Nav1.7 blocker (IC50 = 2.5 nM). Also inhibits Nav1.1, Nav1.2, Nav1.3 and Nav1.6 in the nanomolar range. Exhibits no effects on Cav channels or nAChR at 5 μM. Demonstrates analgesic activity in vivo; antagonizes effects of scorpion-venom toxin OD1 at Nav1.7.